Curis (CRIS) Gets a Buy Rating from JonesTrading


JonesTrading analyst Soumit Roy reiterated a Buy rating on Curis (CRIS) today. The company’s shares closed last Monday at $8.20, close to its 52-week high of $8.66.

According to TipRanks.com, Roy is a top 100 analyst with an average return of 57.5% and a 62.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics.

Currently, the analyst consensus on Curis is a Strong Buy with an average price target of $9.50, a 15.9% upside from current levels. In a report issued on December 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.66 and a one-year low of $0.62. Currently, Curis has an average volume of 8.11M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts